Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 27, 2019
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that JAMA Network Open (www.jamanetwork.com) published results of SUNRISE 1 (Study 304), a pivotal Phase 3...
-
Dec 23, 2019Approval Based on Robust Clinical Development Program That Included Two Pivotal Trials of Nearly 2,000 Patients
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the U.S. Food and Drug Administration (FDA) approved DAYVIGO™ (lemborexant) 5 mg and 10 mg for the treatment of...
-
Dec 10, 2019
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced that new data findings for two investigational assets in its robust dementia pipeline were presented at the 12th...
-
Dec 10, 2019
Eisai announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (marketed as HALAVEN®) will be presented during the 42nd San Antonio...
-
Dec 9, 2019Eisai presents key data at the 2019 American Epilepsy Society Annual Meeting
Eisai Inc. presented the latest healthcare economic (HCEI) data for FYCOMPA® (perampanel) CIII at the 2019 American Epilepsy Society Annual Meeting in Baltimore, Maryland. Cumulatively, more than...